FDA BRIEF: Week of June 5, 2017


UDI Compliance Dates for Class I and Unclassified Devices

Unique Device Identification (UDI) system established in 2013  to adequately identify devices though distribution and use

Extending  compliance dates for lower-risk medical devices

  • For class I and unclassified devices
  • Not applicable to class I/unclassified implantable, life-supporting or life-sustaining devices – should already be compliant
  • Guidance to provide enforcement discretion policy for labeling, data submission, standard date formatting, and direct mark requirements

READ

Humanitarian Use Devices; 21st Century Cures Act; Technical Amendment

The 21st Century Cures Act removed local Institutional Review Board (IRB) review

  • Rely on a central IRB
  • Investigational Device Exemption (IDE) studies
  • Humanitarian Device Exemption (HDE) devices
  • Same measures and policies to protect patients who are involved in clinical research or are treated with Human Device Exemption (HDE) for HUD

READ

Wrinkle Filler

Dermal fillers are FDA approved medical device implants

  • to create smoother and/or fuller facial appearance including nasolabial folds, cheeks and lips
  • increasing volume of back of hand

NOT approved for breast, buttock augmentation, increase fullness of the feet, implant into bone, tendon, ligament, or muscle

Risks and Serious Adverse Events reported with use

Information for Healthcare Providers and Patients

Approved Dermal Fillers

 

Endo Pharmaceuticals

FDA Requests Removal of Opana ER for Abuse-Related Risks

FDA requested Endo Pharmaceuticals removal of reformulated injectable Opana ER

  • concern that benefits may no longer outweigh its risks
  • public health consequences of abuse.
  • first time to remove marketed opioid pain medication from sale

FDA decision based on

  • review of all available postmarketing data
  • significant shift in route of abuse (nasal to injection) after product reformulation
  • injection abuse associated with serious HIV and hepatitis outbreaks, cases of  serious blood disorder (thrombotic microangiopathy)
  • March 2017 FDA advisory committee voted that benefits no longer outweigh risks

FDA will continue to examine risk-benefit profile of all approved opioid analgesic products in response to public health crisis

READ

 

Outsmarting Poison Ivy and Other Poisonous Plants

READ


 

 

 

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s